EIDD-2801 pharmacokinetics study in cats with naturally occurring feline infectious peritonitis
Background and purpose of the trial
Feline infectious peritonitis (FIP) has been a challenge for veterinarians and a devastating disease among cats for over half a century and there is currently no legally available treatment option for FIP.
This study seeks to determine the activity/pharmacokinetics (how the body interacts with administered medication) of the EIDD-2801 antiviral in cats with naturally occurring FIP. Antiviral (EIDD-2801) therapy is currently not approved but available under FDA Emergency Use Authorization for use in people.
Incentives
Drug costs, exam fees, coronavirus PCR, and recheck bloodwork and urinalysis during the 12 weeks of the study are all covered.
condition(s)
eligibility information
Candidates will need to meet the following criteria to qualify for this clinical trial:
- Cats with suspected or confirmed diagnosis of feline infectious peritonitis (FIP)
- Owners must be willing to return to CSU at day 7 and weeks 4, 8, and 12 for recheck of bloodwork.
The following criteria exclude candidates from qualifying for this clinical trial:
- Cats that need hospitalization for intravenous fluid therapy or have severe anemia requiring blood transfusion.
- Cats with IRIS CKD stage 3 and 4
- Cats with congestive heart failure
- Cats with diabetes mellitus and/or uncontrolled hyperthyroidism
- Cats with that have other systemic infectious diseases (eg. FIV, FeLV)
- Cats that received previous treatment with immunosuppressive medications (eg. corticosteroids) or antiviral medications
Enrollment Deadline
Enrollment ends December 31, 2024
contact information
Please contact Dr. Petra Cerna if you believe you have a cat that might qualify for this clinical trial.
